Publication:
Assessing evidence of interaction between smoking and warfarin: A systematic review and meta-analysis

dc.contributor.authorSurakit Nathisuwanen_US
dc.contributor.authorPiyameth Dilokthornsakulen_US
dc.contributor.authorNathorn Chaiyakunapruken_US
dc.contributor.authorTatiya Moraraien_US
dc.contributor.authorThararat Yodtingen_US
dc.contributor.authorNichakorn Piriyachananusornen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherNaresuan Universityen_US
dc.contributor.otherUniversity of Queenslanden_US
dc.contributor.otherUniversity of Wisconsin Madisonen_US
dc.date.accessioned2018-05-03T08:32:13Z
dc.date.available2018-05-03T08:32:13Z
dc.date.issued2011-05-01en_US
dc.description.abstractBackground: Chronic smoking, theoretically, can interfere with warfarin metabolism through enzyme-inducing effects of polycyclic aromatic hydrocarbons. However, clinical evidence of interactions between warfarin and smoking are inconclusive. This study aimed to systematically review all relevant clinical evidence of this interaction. Methods: We performed a systematic search using computerized databases, including PubMed, Embase, Cochrane Central Register of Controlled Trials, CINAHL, Allied and Complementary Medicine, PsycINFO, International Pharmaceutical Abstracts, and ClinicalTrials.gov from 1966 to December 2008. Keywords included "warfarin" with "smoking," "tobacco," "cigarette," and "polycyclic aromatic hydrocarbons." Original articles reporting interaction between warfarin and smoking were included. All articles were reviewed independently by two investigators for study design, population, outcomes, and quality of evidence. Results: Of the 1,240 studies retrieved, one experimental pharmacokinetic study and 12 crosssectional studies were included. The pooled analyses of multivariate studies suggested that smoking was associated with a 12.1 3% (95% CI, 6.999-17.265; P < .001) increase in warfarin dosage requirement and an additional 2.26 mg (95% CI, 2.529-7.042; P=5.355) per week compared with nonsmoking. Additional sensitivity analysis of four multivariate studies with adjustment for pharmacogenomic factors suggested that smoking was associated with a 13.21% (95% CI, 8.59%-17.83%; P < .001) increase in warfarin dosage requirement compared with nonsmokers. Results of an experimental pharmacokinetic study lend theoretical support to the findings. Conclusions: Evidence suggests that smoking may potentially cause significant interaction with warfarin by increasing warfarin clearance, which leads to reduced warfarin effects. Close monitoring of warfarin therapy should be instituted when there is a change in smoking status of patients requiring warfarin therapy. © 2011 American College of Chest Physicians.en_US
dc.identifier.citationChest. Vol.139, No.5 (2011), 1130-1139en_US
dc.identifier.doi10.1378/chest.10-0777en_US
dc.identifier.issn19313543en_US
dc.identifier.issn00123692en_US
dc.identifier.other2-s2.0-79955749858en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/12520
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79955749858&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleAssessing evidence of interaction between smoking and warfarin: A systematic review and meta-analysisen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79955749858&origin=inwarden_US

Files

Collections